Currently, Zymeworks BC Inc [ZYME] is trading at $13.07, up 4.98%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZYME shares have gain 8.20% over the last week, with a monthly amount glided 15.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, JP Morgan upgraded its rating to Overweight on December 16, 2024, and kept the price target unchanged to $18. On November 07, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $25 on the stock. Wells Fargo downgraded its rating to a Equal Weight but stick to its price target of $12 on November 01, 2024. H.C. Wainwright reiterated a Neutral rating for this stock on January 04, 2023, and downed its price target to $8. In a note dated December 20, 2022, Jefferies upgraded an Buy rating on this stock and boosted its target price from $7.70 to $11.
This stock has fluctuated between a low of $8.21 and a high of $17.70 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $17.8 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $13.07 at the most recent close of the market. An investor can expect a potential return of 36.19% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
Trailing Twelve Months sales for Zymeworks BC Inc [NASDAQ:ZYME] were 93.38M which represents 170.29% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.15%, Pretax Profit Margin comes in at -1.15%, and Net Profit Margin reading is -1.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.32 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zymeworks BC Inc [NASDAQ:ZYME] is 4.71. Further, the Quick Ratio stands at 4.71, while the Cash Ratio is 1.17. Considering the valuation of this stock, the price to sales ratio is 9.83, the price to book ratio is 2.82.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on May 15 ’25 when 49502.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on May 19 ’25 to buy 5919.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 73953.0 shares on Apr 16 ’25.
